The Village Global podcast takes you inside the world of venture capital and technology, featuring enlightening interviews with entrepreneurs, investors and tech industry leaders. Learn more at www.villageglobal.vc.
…
continue reading
Konten disediakan oleh jruss88 and Vox Markets Podcast. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh jruss88 and Vox Markets Podcast atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !
Offline dengan aplikasi Player FM !
1034: Dr Mike Hudson of EDX Medical: Collaboration accelerates access to highly reliable, affordable tests for a range of cancers in the UK & Europe
MP3•Beranda episode
Manage episode 347633559 series 2936804
Konten disediakan oleh jruss88 and Vox Markets Podcast. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh jruss88 and Vox Markets Podcast atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Dr Mike Hudson, CEO of EDX Medical Group #EDX discusses their collaboration with Tianjin Bioscience Diagnostic Technology Co. Ltd which will accelerate access to highly reliable, affordable tests for a range of cancers in the UK & Europe.
Highlights
The programme is a result of a partnership between the Company and Tianjin Bioscience Diagnostic Technology Co. Ltd ("Bioscience"), an internationally active, ISO 13485-certified research-based manufacturer of diagnostic products and reagents. The Company has been selected by Bioscience as its lead partner to validate and commercialise its suite of internationally recognised cancer biomarkers in Europe.
The programme will encompass the validation and clinical deployment of Bioscience's digital chemiluminescence immunoassay technology for an initial 10 cancer biomarkers, including the key glycoprotein Carbohydrate Antigens: CA-15-3, CA19-9, CA-125, and CA-72-4. These biomarkers are recognised as important tools to improve the clinical management of a range of cancers and will be deployed both individually and in combination using the Bioscience automated analysers.
To read the full RNS click here
Highlights
The programme is a result of a partnership between the Company and Tianjin Bioscience Diagnostic Technology Co. Ltd ("Bioscience"), an internationally active, ISO 13485-certified research-based manufacturer of diagnostic products and reagents. The Company has been selected by Bioscience as its lead partner to validate and commercialise its suite of internationally recognised cancer biomarkers in Europe.
The programme will encompass the validation and clinical deployment of Bioscience's digital chemiluminescence immunoassay technology for an initial 10 cancer biomarkers, including the key glycoprotein Carbohydrate Antigens: CA-15-3, CA19-9, CA-125, and CA-72-4. These biomarkers are recognised as important tools to improve the clinical management of a range of cancers and will be deployed both individually and in combination using the Bioscience automated analysers.
To read the full RNS click here
1876 episode
MP3•Beranda episode
Manage episode 347633559 series 2936804
Konten disediakan oleh jruss88 and Vox Markets Podcast. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh jruss88 and Vox Markets Podcast atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Dr Mike Hudson, CEO of EDX Medical Group #EDX discusses their collaboration with Tianjin Bioscience Diagnostic Technology Co. Ltd which will accelerate access to highly reliable, affordable tests for a range of cancers in the UK & Europe.
Highlights
The programme is a result of a partnership between the Company and Tianjin Bioscience Diagnostic Technology Co. Ltd ("Bioscience"), an internationally active, ISO 13485-certified research-based manufacturer of diagnostic products and reagents. The Company has been selected by Bioscience as its lead partner to validate and commercialise its suite of internationally recognised cancer biomarkers in Europe.
The programme will encompass the validation and clinical deployment of Bioscience's digital chemiluminescence immunoassay technology for an initial 10 cancer biomarkers, including the key glycoprotein Carbohydrate Antigens: CA-15-3, CA19-9, CA-125, and CA-72-4. These biomarkers are recognised as important tools to improve the clinical management of a range of cancers and will be deployed both individually and in combination using the Bioscience automated analysers.
To read the full RNS click here
Highlights
The programme is a result of a partnership between the Company and Tianjin Bioscience Diagnostic Technology Co. Ltd ("Bioscience"), an internationally active, ISO 13485-certified research-based manufacturer of diagnostic products and reagents. The Company has been selected by Bioscience as its lead partner to validate and commercialise its suite of internationally recognised cancer biomarkers in Europe.
The programme will encompass the validation and clinical deployment of Bioscience's digital chemiluminescence immunoassay technology for an initial 10 cancer biomarkers, including the key glycoprotein Carbohydrate Antigens: CA-15-3, CA19-9, CA-125, and CA-72-4. These biomarkers are recognised as important tools to improve the clinical management of a range of cancers and will be deployed both individually and in combination using the Bioscience automated analysers.
To read the full RNS click here
1876 episode
すべてのエピソード
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.